查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
治疗性疫苗市场规模及预测 2021 - 2031、全球及地区份额、趋势及成长机会分析报告范围：依产品、技术、最终用户及地理划分
市场调查报告书
商品编码
1666225

治疗性疫苗市场规模及预测 2021 - 2031、全球及地区份额、趋势及成长机会分析报告范围：依产品、技术、最终用户及地理划分

Therapeutic Vaccines Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Technology, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 207 Pages | 订单完成后即时交付

价格

治疗性疫苗市场规模预计将从2024年的12.4亿美元成长到2031年的29.3亿美元；预计 2024-2031 年期间的复合年增长率为 13.0%。慢性病发病率的上升以及疫苗开发的投资和资金的增加是推动治疗性疫苗市场扩大的值得注意的因素。然而，监管挑战阻碍了治疗性疫苗市场的成长。

使用传统技术无法开发可能引起大流行的新兴病原体的疫苗。因此，开发能够快速应对大流行威胁并有效适应应对新出现的变种措施的平台非常重要。创新疫苗平台（例如mRNA疫苗、基于免疫材料的疫苗技术、奈米药物传递系统和基于病毒载体的疫苗）正在彻底改变治疗性疫苗的发展。此外，向更有效率和可客製化的疫苗技术的转变使得可以针对多种疾病（包括癌症、自体免疫疾病和传染病）的疫苗的开发成为可能。 mRNA COVID-19疫苗技术的成功展示了mRNA技术在传染病之外的治疗应用（包括癌症和慢性感染）中的潜力。这些平台可以实现更快、更灵活、更好的可扩展的疫苗生产，从而加速新型治疗性疫苗的开发。

研究人员正在为未来的应用程式开发新平台。例如，哈佛大学 Wyss 研究所的研究小组正在开发一个名为 OMNIVAX 的先驱疫苗平台。这种「一流的基于免疫材料」的疫苗技术旨在创造安全有效的针对病毒和细菌感染的治疗和预防疫苗。注射后，OMNIVAX 疫苗会建立一个支架来吸引树突状免疫细胞，并进行编程以针对特定抗原。然后细胞被释放，接着迁移到附近的淋巴结，在那里启动全身和长期的免疫反应。使用模组化技术，可以将多种抗原整合到单一 OMNIVAX 疫苗中。疫苗技术的进步可能会在未来几年为治疗性疫苗市场带来新的趋势。

基于最终用户的洞察

根据最终用户，治疗性疫苗市场分为医院、诊所和其他。 2024 年，医院部门占据了治疗性疫苗最大的市场份额。医院配备了实施针对癌症和自体免疫疾病的专门治疗所需的先进基础设施。随着癌症等慢性病在全球的发生率持续上升，医院对这些治疗的需求持续存在。医院提供全面的护理，包括诊断服务、治疗和治疗后监测，所有这些对于接受治疗性疫苗治疗的患者都至关重要。此外，医院研究和临床试验的激增也促进了该领域治疗性疫苗市场的扩张。许多治疗性疫苗在医院环境中进行试验，使医疗保健专业人员能够及时了解新疫苗和治疗方法的发展，从而推动治疗性疫苗市场的成长。

世界卫生组织（WHO）、全球癌症事实与数据以及美国癌症协会是编写治疗性疫苗市场报告时参考的主要和次要来源。

目录

第 1 章：简介

第 2 章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 发育基数：
    • 数据三角测量：
    • 国家级资料：

第 4 章：治疗性疫苗市场格局

  • 概述
  • PEST分析

第 5 章：治疗性疫苗市场 - 主要市场动态

  • 治疗性疫苗市场 - 主要市场动态
  • 市场驱动因素
    • 慢性病盛行率上升
    • 增加疫苗研发的投资与资金
  • 市场限制
    • 监管挑战
  • 市场机会
    • 扩展产品线
  • 未来趋势
    • 疫苗技术的进步
  • 驱动因素和限制因素的影响：

第 6 章：治疗性疫苗市场 - 全球市场分析

  • 治疗性疫苗市场收入，2021-2031 年
  • 治疗性疫苗市场预测分析

第 7 章：治疗性疫苗市场分析 - 按产品

  • 癌症疫苗
  • 传染病疫苗
  • 其他的

第 8 章：治疗性疫苗市场分析 - 按技术

  • 同种异体疫苗
  • 自体疫苗

第 9 章：治疗性疫苗市场分析 - 按最终用户

  • 医院
  • 诊所
  • 其他的

第 10 章：治疗性疫苗市场 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 亚太地区其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：治疗性疫苗市场-产业格局

  • 概述
  • 治疗性疫苗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 12 章：公司简介

  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd
  • Merck & Co Inc
  • Amgen Inc
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

第 13 章：附录

Product Code: TIPRE00039849

The therapeutic vaccines market size is expected to grow from US$ 1.24 billion in 2024 to US$ 2.93 billion by 2031; it is projected to register a CAGR of 13.0% during 2024-2031. The rising prevalence of chronic diseases, and increasing investments and funding for vaccine development are noteworthy factors contributing to the expansion of the therapeutic vaccines market size. However, regulatory challenges hinder the therapeutic vaccines market growth.

Developing vaccines against emerging pathogens that possess the potential to cause pandemics is not feasible using conventional technologies. As a result, it is important to develop platforms that can respond rapidly to pandemic threats and adapt effectively to measures taken to tackle emerging variants. Innovative vaccine platforms-such as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccines-are revolutionizing the development of therapeutic vaccines. Further, the shift toward more efficient and customizable vaccine technologies has enabled the development of vaccines that can target several diseases, including cancers, autoimmune conditions, and infectious diseases. The success of mRNA COVID-19 vaccine technology showcases promises in the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These platforms allow for quicker, more flexible, and better scalable vaccine production, accelerating the development of new therapeutic vaccines.

Researchers are developing novel platforms for future applications. For instance, a research team at the Wyss Institute at Harvard University is developing a pioneering vaccine platform known as OMNIVAX. This "first-in-class immuno-material-based" vaccine technology aims to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial infections. Upon injection, OMNIVAX vaccines establish a scaffold to attract dendritic immune cells, programming them to target a specific antigen. The cells are then released, followed by their migration to nearby lymph nodes, where they initiate a systemic and prolonged immune response. Using modular technology, multiple antigens can be incorporated into a single OMNIVAX vaccine. The advancements in vaccine technology are likely to bring new trends in the therapeutic vaccines market in the coming years.

End User-Based Insights

Based on end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment held the largest therapeutic vaccines market share in 2024. Therapeutic vaccines are increasingly being recognized as a critical part of the treatment of cancer and other chronic diseases, which are frequently managed in hospital settings. Hospitals are equipped with the advanced infrastructure required to administer specialized therapies against cancer and autoimmune diseases. As the prevalence of chronic diseases, including cancer, continues to rise globally, hospitals generate a persistent demand for these treatments. Hospitals offer comprehensive care, including diagnostic services, treatment, and post-therapy monitoring, all of which are crucial for patients undergoing therapeutic vaccine treatments. Additionally, an upsurge in hospital-based research and clinical trials contributes to the expansion of the therapeutic vaccines market for this segment. Many therapeutic vaccines undergo trials within hospital environments, enabling healthcare professionals to stay updated on the development of new vaccines and treatments, fueling the therapeutic vaccines market growth.

World Health Organization's (WHO), Global Cancer Facts & Figures, and the American Cancer Society are among the primary and secondary sources referred to while preparing the therapeutic vaccines market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Therapeutic Vaccines Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Therapeutic Vaccines Market - Key Market Dynamics

  • 5.1 Therapeutic Vaccines Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Conditions
    • 5.2.2 Increasing Investments and Funding for Vaccine Development
  • 5.3 Market Restraints
    • 5.3.1 Regulatory Challenges
  • 5.4 Market Opportunities
    • 5.4.1 Extending Product Pipeline
  • 5.5 Future Trends
    • 5.5.1 Advancements in Vaccine Technology
  • 5.6 Impact of Drivers and Restraints:

6. Therapeutic Vaccines Market - Global Market Analysis

  • 6.1 Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • 6.2 Therapeutic Vaccines Market Forecast Analysis

7. Therapeutic Vaccines Market Analysis - by Product

  • 7.1 Cancer Vaccines
    • 7.1.1 Overview
    • 7.1.2 Cancer Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 7.2 Infectious Disease Vaccines
    • 7.2.1 Overview
    • 7.2.2 Infectious Disease Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 7.3 Others
    • 7.3.1 Overview
    • 7.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

8. Therapeutic Vaccines Market Analysis - by Technology

  • 8.1 Allogenic Vaccine
    • 8.1.1 Overview
    • 8.1.2 Allogenic Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 8.2 Autologous Vaccine
    • 8.2.1 Overview
    • 8.2.2 Autologous Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

9. Therapeutic Vaccines Market Analysis - by End User

  • 9.1 Hospitals
    • 9.1.1 Overview
    • 9.1.2 Hospitals: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 9.2 Clinics
    • 9.2.1 Overview
    • 9.2.2 Clinics: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

10. Therapeutic Vaccines Market - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Therapeutic Vaccines Market Overview
    • 10.1.2 North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.1.2.1 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.1.2.2 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.1.2.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.1.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.1.3.1 United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.1.3.1.1 United States: Therapeutic Vaccines Market Breakdown, by Product
        • 10.1.3.1.2 United States: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.1.3.1.3 United States: Therapeutic Vaccines Market Breakdown, by End User
      • 10.1.3.2 Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.1.3.2.1 Canada: Therapeutic Vaccines Market Breakdown, by Product
        • 10.1.3.2.2 Canada: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.1.3.2.3 Canada: Therapeutic Vaccines Market Breakdown, by End User
      • 10.1.3.3 Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.1.3.3.1 Mexico: Therapeutic Vaccines Market Breakdown, by Product
        • 10.1.3.3.2 Mexico: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.1.3.3.3 Mexico: Therapeutic Vaccines Market Breakdown, by End User
  • 10.2 Europe
    • 10.2.1 Europe Therapeutic Vaccines Market Overview
    • 10.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.2.2.1 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.2.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.2.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.2.3.1 Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.1.1 Germany: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.1.2 Germany: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.1.3 Germany: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.2 United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.2.1 United Kingdom: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.2.2 United Kingdom: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.2.3 United Kingdom: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.3 France: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.3.1 France: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.3.2 France: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.3.3 France: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.4 Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.4.1 Italy: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.4.2 Italy: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.4.3 Italy: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.5 Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.5.1 Spain: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.5.2 Spain: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.5.3 Spain: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.6 Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.6.1 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.6.2 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.6.3 Rest of Europe: Therapeutic Vaccines Market Breakdown, by End User
  • 10.3 Asia Pacific
    • 10.3.1 Asia Pacific Therapeutic Vaccines Market Overview
    • 10.3.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.3.2.1 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.3.2.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.3.2.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.3.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.3.3.1 China: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.1.1 China: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.1.2 China: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.1.3 China: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.2 Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.2.1 Japan: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.2.2 Japan: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.2.3 Japan: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.3 India: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.3.1 India: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.3.2 India: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.3.3 India: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.4 South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.4.1 South Korea: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.4.2 South Korea: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.4.3 South Korea: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.5 Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.5.1 Australia: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.5.2 Australia: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.5.3 Australia: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.6 Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.6.1 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.6.2 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.6.3 Rest of APAC: Therapeutic Vaccines Market Breakdown, by End User
  • 10.4 Middle East & Africa
    • 10.4.1 Middle East & Africa Therapeutic Vaccines Market Overview
    • 10.4.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.4.2.1 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.4.2.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.4.2.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.4.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.4.3.1 Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.1.1 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.1.2 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.1.3 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by End User
      • 10.4.3.2 South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.2.1 South Africa: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.2.2 South Africa: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.2.3 South Africa: Therapeutic Vaccines Market Breakdown, by End User
      • 10.4.3.3 United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.3.1 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.3.2 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.3.3 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by End User
      • 10.4.3.4 Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.4.1 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.4.2 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.4.3 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by End User
  • 10.5 South & Central America
    • 10.5.1 South & Central America Therapeutic Vaccines Market Overview
    • 10.5.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.5.2.1 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.5.2.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.5.2.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.5.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.5.3.1 Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.5.3.1.1 Brazil: Therapeutic Vaccines Market Breakdown, by Product
        • 10.5.3.1.2 Brazil: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.5.3.1.3 Brazil: Therapeutic Vaccines Market Breakdown, by End User
      • 10.5.3.2 Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.5.3.2.1 Argentina: Therapeutic Vaccines Market Breakdown, by Product
        • 10.5.3.2.2 Argentina: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.5.3.2.3 Argentina: Therapeutic Vaccines Market Breakdown, by End User
      • 10.5.3.3 Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.5.3.3.1 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Product
        • 10.5.3.3.2 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.5.3.3.3 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by End User

11. Therapeutic Vaccines Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Therapeutic Vaccines Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Dendreon
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 BioNTech SE
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Serum Institute of India Pvt. Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Merck & Co Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Amgen Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 ISA Pharmaceuticals BV
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 INOVIO Pharmaceuticals Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Transgene SA
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 THERAVECTYS SA
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 CureVac SE
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Therapeutic Vaccines Market Segmentation
  • Table 2. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 3. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 4. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 5. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 6. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 7. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 8. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 9. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 10. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 11. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 12. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 13. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 14. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 15. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 16. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 17. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 18. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 19. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 20. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 21. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 22. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 23. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 24. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 25. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 26. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 27. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 28. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 29. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 30. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 31. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 32. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 33. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 34. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 35. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 36. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 37. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 38. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 39. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 40. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 41. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 42. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 43. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 44. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 45. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 46. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 47. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 48. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 49. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 50. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 51. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 52. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 53. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 54. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 55. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 56. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 57. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 58. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 59. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 60. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 61. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 62. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 63. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 64. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 65. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 66. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 67. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 68. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 69. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 70. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 71. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 72. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 73. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 74. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 75. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 76. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 77. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 78. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 79. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 80. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 81. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 82. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 83. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
  • Table 84. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
  • Table 85. Glossary of Terms, Therapeutic Vaccines Market

List Of Figures

  • Figure 1. Therapeutic Vaccines Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 6. Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
  • Figure 7. Cancer Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 8. Infectious Disease Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 9. Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 10. Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
  • Figure 11. Allogenic Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 12. Autologous Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 13. Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
  • Figure 14. Hospitals: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 15. Clinics: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 16. Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 17. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 18. North America: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 19. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 20. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 21. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 22. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 23. Europe: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 24. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 25. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 26. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 27. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 28. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 29. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 30. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 31. Asia Pacific: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 32. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 33. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 34. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 35. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 36. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 37. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 38. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 39. Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 40. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 41. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 42. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 43. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 44. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 45. South & Central America: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 46. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 47. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 48. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 49. Growth Strategies in the Therapeutic Vaccines Market